Moreover, in vivo model of diethylnitrosamine (DEN) induced hepatocellular carcinoma (HCC) in rats, daily orally administrated with FBRP at doses of 1 g/kg, for 18 weeks, effectively reduced the serum levels of ALT, AST, ALP, TP, HA and alpha fetoprotein (AFP), significantly suppressed the liver tissues expression of p-PI3K, p-AKT, p-IKkB, and p-NF-κB, as well as the ratios of p-IKkB/total IKkB and p-NF-κB/total NF-κB, suggested FBRP may be a promising candidate drug for reduction of fibrogenesis and prevention of HCC via blocking PI3K/AKT/NF-κB activation (Zhang et al., 2020). Here, IKBKB is linked to hepatocellular carcinoma.